BONESUPPORT HOLDING AB (publ) – publishes Q2 2024 Interim report
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2024.
55% SALES GROWTH IN THE FIRST SIX MONTHS
APRIL - JUNE 2024
- Net sales increased by 57 percent (55 percent at constant exchange rates) and amounted to SEK 219.8 million (140.4).
- The North America (NA) segment reported a sales growth of 67 percent (66 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (26 percent at constant exchange rates).
- The gross margin amounted to 92.3 percent (91.3).
- The operating result before effects from the Group’s incentive programs amounted to SEK 36.0 million (13.6). Reported operating result amounted to SEK 28.7 million (6.0).
- Earnings per share before dilution were SEK 0.42 (0.08).
- Earnings per share after dilution were SEK 0.41 (0.08).
JANUARY - JUNE 2024
- Net sales increased by 55 percent (54 percent at constant exchange rates) and amounted to SEK 404.2 million (260.1).
- The North America (NA) segment reported a sales growth of 66 percent (65 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (26 percent at constant exchange rates).
- The gross margin amounted to 92.4 percent (90.9)
- Operating result before effects from the Group’s incentive programs amounted to SEK 77.6 million (18.2). Reported operating result amounted to SEK 61.0 million (6.7).
- Earnings per share before dilution were SEK 0.75 (0.09).
- Earnings per share after dilution were SEK 0.74 (0.08).
"Strong sales – raised guidance for 2024." Emil Billbäck, CEO
EVENTS DURING THE PERIOD
- In June, the results of an Australian study in the treatment of bone infection resulting from diabetes-related foot ulcers were presented. The results of the study show that the use of CERAMENT G or CERAMENT V not only significantly reduces the risk of amputation and surgical procedures, but also promotes effective healing and shorter hospital stays compared to the control group.
- CMS announced proposal to extend NTAP for CERAMENT G in the US until September 2025. Final decision expected in August 2024.
EVENTS AFTER THE PERIOD
- The FDA announced that CERAMENT V must follow the regulatory 510(k) process for applying for market authorization.
- Anna Stegmark is hired as Executive Vice President Quality and Regulatory Affairs.
- Increase in forecast for 2024 sales growth to over 50 percent (previous forecast was over 40 percent).